Capitolis Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Capitolis Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,493	Closed	-$473K	–	150
2022 Q1	$473K	Sell	4,493 -57,000	-93%	-$5.55M	0.02%	97
2021 Q4	$6.63M	Hold	61,493	–	–	0.04%	286
2021 Q3	$6.95M	Buy	+61,493	New	+$6.38M	0.06%	211

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Capitolis Advisors's HZNP Position: Q2 2022 in Review

Capitolis Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 4,493 shares — an estimated $473K sold.

Capitolis Advisors first reported a position in HZNP in Q3 2021 and held it in 3 quarters. The position peaked at $6.95M in Q3 2021. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Capitolis Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Capitolis Advisors sold 4,493 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $473K.
Capitolis Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 3 quarters.
Capitolis Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.95M in Q3 2021.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Capitolis Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.